Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Rational Vaccine Development- Borrow Group

  • Borrow Group

Our research seeks to inform the rational design of effective prophylactic and therapeutic approaches to combat HIV-1 infection and target blood cancers; and to understand basic principles of immune function and regulation that have broad application to development of vaccines and therapeutic strategies for infections, tumours and autoimmune disorders.

Our team

Latest publications

What if Every Patient’s Immune System Could be Guided by the World’s Most Powerful Computers to Fight Cancer? The UK Cancer Vaccines AI and Supercompute Project

Journal article

Bryan ME. et al, (2026), EMJ Innovation, 10, 74 - 79

Targeting MHC-E as a new strategy for vaccines and immunotherapeutics.

Journal article

Früh K. et al, (2026), Nature reviews. Immunology, 26, 52 - 66

Bromodomain and extra-terminal protein inhibitors modulate natural killer cell function and differentiation.

Journal article

Geanes ES. et al, (2026), Scientific reports, 16

Molecular basis for selection and inhibition of HIV-1 escape virus by T cells and KIR2DL2+NK cells

Journal article

Chikata T. et al, (2025), Nature Communications, 16

Molecular basis for selection and inhibition of HIV-1 escape virus by T cells and KIR2DL2+NK cells.

Journal article

Chikata T. et al, (2025), Nature communications, 16

A cytoplasmic motif in HLA-E that drives clathrin-mediated endocytosis and VCP-associated postendocytic trafficking.

Journal article

He W. et al, (2025), Proceedings of the National Academy of Sciences of the United States of America, 122

HLA-E-VL9 antibodies enhance NK cell and CD8 + T cell cytotoxicity against HIV-infected CD4 + T cells.

Preprint

Hwang JK. et al, (2025)

In vivo enhancement of tumour-specific T cells via peptide-MHC-pseudotyped retroviral gene delivery.

Journal article

Kwong H. and Borrow P., (2025), Nature reviews. Immunology, 25

Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins.

Journal article

Brackenridge S. et al, (2024), Journal of virology, 98

Integrating patient and public involvement and engagement in translational medicine.

Journal article

Shaw KL. et al, (2024), Lancet (London, England), 404, 828 - 831